COVID-19 vaccination status, side effects, and perceptions among breast cancer survivors: a cross-sectional study in China

Abstract

IntroductionBreast cancer is the most prevalent malignancy in patients with coronavirus disease 2019 (COVID-19). However, vaccination data of this population are limited.MethodsA cross-sectional study of COVID-19 vaccination was conducted in China. Multivariate logistic regression models were used to assess factors associated with COVID-19 vaccination status.ResultsOf 2,904 participants, 50.2% were vaccinated with acceptable side effects. Most of the participants received inactivated virus vaccines. The most common reason for vaccination was “fear of infection” (56.2%) and “workplace/government requirement” (33.1%). While the most common reason for nonvaccination was “worry that vaccines cause breast cancer progression or interfere with treatment” (72.9%) and “have concerns about side effects or safety” (39.6%). Patients who were employed (odds ratio, OR = 1.783, p = 0.015), had stage I disease at diagnosis (OR = 2.008, p = 0.019), thought vaccines could provide protection (OR = 1.774, p = 0.007), thought COVID-19 vaccines were safe, very safe, not safe, and very unsafe (OR = 2.074, p < 0.001; OR = 4.251, p < 0.001; OR = 2.075, p = 0.011; OR = 5.609, p = 0.003, respectively) were more likely to receive vaccination. Patients who were 1–3 years, 3–5 years, and more than 5 years after surgery (OR = 0.277, p < 0.001; OR = 0.277, p < 0.001, OR = 0.282, p < 0.001, respectively), had a history of food or drug allergies (OR = 0.579, p = 0.001), had recently undergone endocrine therapy (OR = 0.531, p < 0.001) were less likely to receive vaccination.ConclusionCOVID-19 vaccination gap exists in breast cancer survivors, which could be filled by raising awareness and increasing confidence in vaccine safety during cancer treatment, particularly for the unemployed individuals.

Outcomes of COVID‐19 in patients with lymphomas participating in registered clinical trials: A real‐world study from China in the Omicron outbreak era

“…However, the concerns of vaccines included cancer progression, potential long-term toxicity, or interfere with treatment resulted in a low acceptance of the vaccine in cancer patients in China. [29][30][31] In our study, only 34.5% of patients were vaccinated against COVID-19 and 10% of patients had received the third dose of vaccines. The lower vaccine serologic response was reported in HM patients, particularly those with lymphoid cancers and/or receiving anti-CD20 therapy with impaired immune function [32][33][34][35] ; thus, the protective effect of vaccine might be limited in these patients.…”